Table II.
10B concentration (μg/g=ppm) in tumors and boron dose rate (cGy/h).
| Variable | Without nicotinamide or MTH | With nicotinamide | With MTH |
|---|---|---|---|
| 10B concentration (μg/g) | |||
| Without bevacizumab | |||
| BPA | 6.9±0.8 | 7.3±1.0 | 8.3±1.1 |
| BSH | 7.2±0.9 | 8.4±1.1 | 7.9±1.0 |
| With bevacizumab | |||
| BPA | 7.2±0.9 | 7.4±1.1 | 8.6±1.2 |
| BSH | 8.0±1.0 | 8.6±1.2 | 8.7±1.2 |
| Boron dose rate (cGy/h) | |||
| Without bevacizumab | |||
| BPA | 184.2±21.4 | 194.9±26.7 | 221.6±29.4 |
| BSH | 192.2±24.0 | 224.3±29.4 | 210.9±26.7 |
| With bevacizumab | |||
| BPA | 192.2±24.0 | 197.6±29.4 | 229.6±32.0 |
| BSH | 212.7±26.7 | 229.6±32.0 | 231.3±32.0 |
Data are presented as mean ± standard error (n=9). MTH, mild temperature hyperthermia; BPA, L-para-boronophenylalanine-10B; BSH, sodium mercaptoundecahydrododecaborate-10B.